These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 2952907)

  • 1. Amine accumulation in Parkinson's disease and other disorders.
    Willis GL
    Neurosci Biobehav Rev; 1987; 11(1):97-105. PubMed ID: 2952907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aminergic systems in Alzheimer's disease and Parkinson's disease.
    D'Amato RJ; Zweig RM; Whitehouse PJ; Wenk GL; Singer HS; Mayeux R; Price DL; Snyder SH
    Ann Neurol; 1987 Aug; 22(2):229-36. PubMed ID: 3477996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea.
    Huot P; Lévesque M; Parent A
    Brain; 2007 Jan; 130(Pt 1):222-32. PubMed ID: 17142832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent developments in Parkinson's disease and Huntington's chorea.
    Barbeau A
    Int J Neurol; 1976; 11(1):17-27. PubMed ID: 138661
    [No Abstract]   [Full Text] [Related]  

  • 5. Endocannabinoids and Neurodegenerative Disorders: Parkinson's Disease, Huntington's Chorea, Alzheimer's Disease, and Others.
    Fernández-Ruiz J; Romero J; Ramos JA
    Handb Exp Pharmacol; 2015; 231():233-59. PubMed ID: 26408163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parkinson's disease: distribution of Lewy bodies and monoamine neuron system.
    Ohama E; Ikuta F
    Acta Neuropathol; 1976 Apr; 34(4):311-9. PubMed ID: 179263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Involvement of non-opioid peptides in the pathogenesis of neurological and psychiatric disorders: evidence from CSF and post-mortem studies.
    Nemeroff CB; Bissette G
    Prog Clin Biol Res; 1985; 192():333-41. PubMed ID: 2934745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebral metabolic relationships for selected brain regions in Alzheimer's, Huntington's, and Parkinson's diseases.
    Metter EJ; Riege WH; Kameyama M; Kuhl DE; Phelps ME
    J Cereb Blood Flow Metab; 1984 Dec; 4(4):500-6. PubMed ID: 6238975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amine accumulation: a possible precursor of Lewy body formation in Parkinson's disease.
    Sandyk R; Willis GL
    Int J Neurosci; 1992 Sep; 66(1-2):61-74. PubMed ID: 1304571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases.
    Seeman P; Bzowej NH; Guan HC; Bergeron C; Reynolds GP; Bird ED; Riederer P; Jellinger K; Tourtellotte WW
    Neuropsychopharmacology; 1987 Dec; 1(1):5-15. PubMed ID: 2908095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses?
    Beal MF
    Ann Neurol; 1992 Feb; 31(2):119-30. PubMed ID: 1349466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of striatal histamine H2 receptors in Huntington's chorea but not in Parkinson's disease: comparison with animal models.
    Martínez-Mir MI; Pollard H; Moreau J; Traiffort E; Ruat M; Schwartz JC; Palacios JM
    Synapse; 1993 Nov; 15(3):209-20. PubMed ID: 7904088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxidative stress and neurotoxicity.
    Sayre LM; Perry G; Smith MA
    Chem Res Toxicol; 2008 Jan; 21(1):172-88. PubMed ID: 18052107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Presence of tau pathology within foetal neural allografts in patients with Huntington's and Parkinson's disease.
    Cisbani G; Maxan A; Kordower JH; Planel E; Freeman TB; Cicchetti F
    Brain; 2017 Nov; 140(11):2982-2992. PubMed ID: 29069396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunocytochemical studies on the basal ganglia and substantia nigra in Parkinson's disease and Huntington's chorea.
    Waters CM; Peck R; Rossor M; Reynolds GP; Hunt SP
    Neuroscience; 1988 May; 25(2):419-38. PubMed ID: 2456487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of Reactive Oxygen Species in the Pathogenesis of Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease: A Mini Review.
    Manoharan S; Guillemin GJ; Abiramasundari RS; Essa MM; Akbar M; Akbar MD
    Oxid Med Cell Longev; 2016; 2016():8590578. PubMed ID: 28116038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta-adrenergic receptor subtypes in the basal ganglia of patients with Huntington's chorea and Parkinson's disease.
    Waeber C; Rigo M; Chinaglia G; Probst A; Palacios JM
    Synapse; 1991 Aug; 8(4):270-80. PubMed ID: 1656540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serotonergic-dopaminergic interactions and extrapyramidal function.
    Chase TN
    Adv Biochem Psychopharmacol; 1974; 11(0):377-85. PubMed ID: 4367649
    [No Abstract]   [Full Text] [Related]  

  • 19. Alterations in angiotensin AT1 and AT2 receptor subtype levels in brain regions from patients with neurodegenerative disorders.
    Ge J; Barnes NM
    Eur J Pharmacol; 1996 Feb; 297(3):299-306. PubMed ID: 8666063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Free radical damage and oxidative stress in Huntington's disease.
    Borlongan CV; Kanning K; Poulos SG; Freeman TB; Cahill DW; Sanberg PR
    J Fla Med Assoc; 1996 May; 83(5):335-41. PubMed ID: 8666972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.